Nature Communications

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Blood

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

European Journal of Haematology

Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Indian Journal of Hematology and Blood Transfusion

Renal impairment in myeloproliferative neoplasms: An under-reported complication

Blood Neoplasia

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Blood Work

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow